Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposiu...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo and ZYTIGA® pl...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Higher Intensity Therapy and Surgical Risk in Esophageal Cancer Higher Intensity Therapy and Surgical Risk in Esophageal Cancer
Combining standard neoadjuvant chemotherapy for locally advanced esophageal cancer with either radiation or docetaxel did not increase the risk of surgical complications, investigators in the JCOG1109 trial reported.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® in combina...
Source: Johnson and Johnson - May 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
How to Think About Your Cancer Care in the Time of COVID-19
Getting the news that you have cancer is overwhelming and frightening. The COVID-19 crisis adds another layer of anxiety. But know this: you can protect yourself from COVID-19 without compromising your cancer treatment. Don’t panic. In the vast majority of cases, a diagnosis of cancer is not an emergency even though it feels like one. There is time to learn about your options and sort out what is right for you.
For now, there will be changes to how we do things. Some of the changes will feel disruptive, but many will lead to better, more patient-centered care. Minimizing your chances of exposure to the virus doesn&rs...
Source: TIME: Health - April 28, 2020 Category: Consumer Health News Authors: Dr. Laura Esserman Tags: Uncategorized COVID-19 Source Type: news
Pre-operative immunotherapy triggers encouraging response in oral cancers
(American Society for Radiation Oncology) A new clinical trial suggests that immunotherapy given before other treatments for oral cavity cancers can elicit an immune response that shrinks tumors, which could provide long-term benefit for patients. In the randomized trial, two neoadjuvant doses of nivolumab given with or without ipilimumab led to complete or partial tumor shrinkage in most cases and did not delay any patients from continuing on to standard treatment. Findings will be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2020 Category: Cancer & Oncology Source Type: news
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet needs continue...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Julia White, MD, Discusses Tailored Local Therapy Treatment in Breast Cancer
The professor of radiation oncology discussed these tailored treatments for when patients receive neoadjuvant chemotherapy, and they get a complete pathologic response. (Source: CancerNetwork)
Source: CancerNetwork - December 17, 2019 Category: Cancer & Oncology Authors: Julia White, MD Source Type: news
ASTRO Issues Guideline for Radiation Tx in Pancreatic Cancer
Evidence reviewed for radiation therapy in adjuvant, neoadjuvant, definitive, and palliative settings (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 19, 2019 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Radiology, Journal, Source Type: news
Mesothelioma Treatment Combines Proton and Photodynamic Therapy
Intraoperative photodynamic therapy combined with novel proton radiation improved survival time significantly for recent patients with advanced-stage pleural mesothelioma.
The study — the first to measure the impact of this combination — involved 10 consecutive patients treated at the University of Pennsylvania’s Abramson Cancer Center.
The treatment regimen resulted in a 90 percent, two-year disease control rate and an impressive 30.3-month median overall survival from the time of diagnosis.
All 10 patients were diagnosed before treatment began with stage 3 or stage 4 disease, which typically results in a 10 to 14-m...
Source: Asbestos and Mesothelioma News - March 12, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Improving Surgery for Mesothelioma with Glowing Tumor Technology
Thoracic surgeon Dr. Sunil Singhal at the Abramson Cancer Center has developed glowing tumor technology that should increase the effectiveness of aggressive surgery for malignant pleural mesothelioma.
Singhal has shown recently that by adding a contrast agent that makes tumor cells glow, a more complete surgery can be done. This potentially avoids the now almost-inevitable cancer recurrence.
“This is a big deal. We could potentially help a lot of patients with this,” Singhal told Asbestos.com. “It could change the entire field [of surgery for mesothelioma].”
Singhal and his colleagues from the Abramson Cancer Cente...
Source: Asbestos and Mesothelioma News - August 9, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news
For patients with esophageal cancer, status of lymph nodes after preoperative therapy determines survival
(American Association for Thoracic Surgery) The status of lymph nodes rather than the status of the primary tumor following preoperative neoadjuvant chemotherapy or chemoradiation therapy is the most important factor that determines whether patients with locally advanced esophageal cancer will survive. The study presented at the AATS 98th Annual Meeting indicates that while preoperative chemotherapy and radiation therapy improve survival of patients with esophageal cancer, patients with malignant lymph nodes following therapy were less likely to survive than patients with no cancer in the lymph nodes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 1, 2018 Category: Cancer & Oncology Source Type: news
CT Abnormality in Patient With Stage II Breast Cancer History
A 57-year-old woman with a history of stage IIB breast cancer (ypT2N1M0) status post neoadjuvant chemotherapy and left partial mastectomy presents to the radiation oncology clinic for CT simulation in preparation for breast radiotherapy. Noncontrast CT scan incidentally found the abnormality depicted with arrows below. (Source: CancerNetwork)
Source: CancerNetwork - September 8, 2017 Category: Cancer & Oncology Authors: Joseph Miccio, MD Tags: Image IQ Source Type: news
Radiation prior to surgery reduces risk of secondary tumors in early-stage breast cancer
(H. Lee Moffitt Cancer Center& Research Institute) Moffitt researchers found that patients who have neoadjuvant radiation therapy have a significantly lower risk of developing a second primary tumor at any site. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 17, 2017 Category: Cancer & Oncology Source Type: news
